

## Carasent AB (publ) publishes prospectus in connection with its listing on Nasdaq Stockholm

**Carasent AB (publ) (“Carasent” or the “Company”) today publishes a prospectus in connection with the Company’s listing of its shares on Nasdaq Stockholm.**

GOTHENBURG, 29 November 2024

On 30 August 2024, it was announced that the Company had adopted a cross-border merger plan with Carasent ASA, with the Company as the acquiring entity, in order to effect the relisting of Carasent ASA’s shares on Nasdaq Stockholm (the “**Relisting**”). On 8 November 2024, it was announced that Nasdaq Stockholm had assessed that Nasdaq Stockholm’s listing requirements have been fulfilled and that Nasdaq Stockholm will approve an application for admission to trading of the Company’s shares, subject to the fulfilment of certain customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority.

The Swedish language prospectus in relation to the Relisting has today been approved by the Swedish Financial Supervisory Authority and is available on the Company’s website, [www.carasent.com](http://www.carasent.com). The prospectus will also be available on the Swedish Financial Supervisory Authority’s website, [www.fi.se](http://www.fi.se).

The cross-border merger is expected to be completed on 4 December 2024, upon which shareholders will have their shares in Carasent ASA exchanged one-for-one with shares in the Company. The last day of trading on Oslo Børs is expected to be 4 December 2024 and the first day of trading on Nasdaq Stockholm is expected to be 9 December 2024. The dates can be changed and if so, this will be separately announced.

Carnegie Investment Bank AB is acting as sole financial advisor to Carasent, Advokatfirman Vinge is acting as legal advisor to Carasent on Swedish legal matters and Advokatfirmaet BAHR are acting as legal advisor to Carasent on Norwegian legal matters.

### **For further information, please contact**

Daniel Öhman, CEO

Tel: +46 70-855 37 07, e-mail: [daniel.ohman@carasent.com](mailto:daniel.ohman@carasent.com)

Svein Martin Bjørnstad, CFO

Tel: +47 979 69 493, e-mail: [svein.martin.bjornstad@carasent.com](mailto:svein.martin.bjornstad@carasent.com)

*The information was submitted for publication, through the agency of the contact persons set out above, on 29 November 2024 at 14.20 CET.*

**Carasent AB (publ) (Nasdaq Stockholm: CARA)** delivers cloud based EHR solutions, with Webdoc as the leading platform, and a broad ecosystem of platform services, including solutions for patient communication and business intelligence. Since 2020 six acquisitions have been completed, adding new products to the portfolio, including the EHR solutions Metodika, Ad Curis and Ad Opus, the business intelligence software Medrave and occupational care platform HPI. The ecosystem of solutions makes Carasent a one-stop shop for clinics and can cover all needs. Carasent believes in

innovation that offers a new kind of accessibility and availability for patients and practices. The growing product portfolio comprises market-leading software solutions developed closely with customers and the respective target market.

### **IMPORTANT INFORMATION**

The publication, release or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in the jurisdictions in which this press release has been published, released or distributed should inform themselves about and observe such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Carasent in any jurisdiction.

This press release does not identify or attempt to identify any risks (direct or indirect) that may be associated with an investment in securities of Carasent. The information contained in this press release is published for background purposes only and does not purport to be complete.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable laws and regulations.

This press release is not a prospectus as defined in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Carasent has not authorized any offer of securities to the public in any member state of the European Economic Area ("EEA").

This press release contains certain forward-looking statements that reflect the Company's current views with respect to future events and financial and operational performance. Words such as "intends", "expects", "anticipates", "may", "plans", "believes", "estimates" and other expressions that are indicative or predictive of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By its nature, forward-looking information involves known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking statements are not guarantees of future performance or development and actual results may differ materially from those expressed in the forward-looking statements.